

Use of glutamine synthetase for treating hyperammonemia

The present invention relates to the use of glutamine synthetase as a protein therapy (such as enzyme replacement protein therapy) for the treatment of hyperammonemia, and in particular to the systemic administration of glutamine synthetase. The glutamine synthetase is thus administered as a protein, or polypeptide, with the aim of increasing circulating levels of glutamine synthetase. The glutamine synthetase may be provided in conjugated or fusion form, to increase its half-life in the circulation. Also provided is a pharmaceutical composition comprising glutamine synthetase. The invention also relates to the uses, methods and compositions involving a combination of the glutamine synthetase protein and an ammonia lowering agent, such as a nitrogen scavenger.

SUMMARY

In one aspect, the present disclosure refers to a glutamine synthetase protein conjugated to polyethylene glycol (PEG). In another aspect, the present disclosure refers to a pharmaceutical composition comprising a glutamine synthetase fusion protein, comprising i) glutamine synthetase and ii) a peptide comprising a) the sequence HHHHHH (6xHis) and b) a linker comprising 2-10 amino acids and comprising the sequence GGGGS; wherein the peptide is provided at the N terminal end of the glutamine synthetase protein and wherein the glutamine synthetase protein is or comprises the protein of SEQ ID NO. 1 or a variant thereof having glutamine synthetase enzyme activity and at least 90% sequence identity to the sequence of SEQ ID NO. 1; and a pharmaceutically acceptable excipient.

In another aspect, the present disclosure refers to a glutamine synthetase protein conjugated at the N-terminal end to a peptide comprising the sequence GGGGS.

In another aspect, the present disclosure refers to a glutamine synthetase protein conjugated at the N terminal end to a peptide comprising the sequence HHHHHH (6xHis) and a linker comprising 2-10 amino acids, wherein the glutamine synthetase protein is the full length protein, preferably comprising 373 or 372 amino acids.

In another aspect, the present disclosure refers to a pharmaceutical composition comprising glutamine synthetase (GS) protein as disclosed herein.

In another aspect, the present disclosure refers to a glutamine synthetase (GS) protein or the pharmaceutical composition as disclosed herein for use in therapy.

In another aspect, the present disclosure refers to a use of a glutamine synthetase (GS) fusion protein or the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating or preventing hyperammonemia by systemic non-oral administration to a subject.

In another aspect, the present disclosure refers to a use of a pharmaceutical composition comprising glutamine synthetase (GS) fusion protein in the manufacture of a medicament for the treating or preventing hyperammonemia by systemic non-oral administration to a subject.

5 In another aspect, the present disclosure refers to the use of a GS protein for the manufacture of a composition for use in combination therapy for the treatment or prevention of hyperammonemia, wherein said medicament is to be administered in combination with a compound which removes ammonia or reduces or inhibits production of ammonia.

10 In yet another aspect, the present disclosure refers to the use of a GS fusion protein as disclosed herein in the manufacture of a first medicament and use of a compound which removes ammonia or reduces or inhibits production of ammonia in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy for the treatment or prevention
15 of hyperammonemia.

In another aspect, the present disclosure refers to a composition comprising a GS protein and a compound which removes ammonia or reduces or inhibits production of ammonia.

20 In another aspect, the present disclosure refers to a pharmaceutical composition comprising a glutamine synthetase fusion protein which i) comprises the sequence of SEQ ID NO. 4; or ii) comprises the sequence of SEQ ID NO. 4 with a deletion of the N-terminal methionine and having glutamine synthetase activity; or iii) is encoded by the sequence of SEQ ID NO. 5; iv) is encoded by the sequence of SEQ ID NO. 5 and has a deletion of the N-terminal methionine and has glutamine
25 synthetase activity; and a pharmaceutical excipient.

In another aspect, the present disclosure refers to a kit comprising i) a glutamine synthetase fusion protein as disclosed herein for systemic non-oral administration and ii) a compound which removes ammonia or reduces or inhibits production of ammonia or an amino acid or urea cycle intermediate or analogue
30 thereof, preferably wherein the

compound which removes ammonia or reduces or inhibits production of ammonia is selected from the group consisting of a compound which reduces the amount of nitrogen, an ion exchange resin (for example Relapsa), an ammonia absorber (such a liposomal based ammonia absorber, for example Versantis), an engineered
5 microbiome that removes ammonia (for example Kaleido Biosciences KB195), Rifaximin and Lactulose.

In yet another aspect, the present disclosure refers to an expression vector encoding a glutamine synthetase fusion protein as disclosed herein.
In yet another aspect, the present disclosure refers to a use of an expression vector
10 encoding a glutamine synthetase fusion protein as disclosed herein in the manufacture of a medicament for the treatment or prevention of hyperammonemia, wherein the vector is for systemic administration.

In yet another aspect, the present disclosure refers to a kit comprising an expression vector as disclosed herein, and a further therapeutic agent, preferably
15 wherein the therapeutic agent is an ammonia lowering agent or an amino acid or urea cycle intermediate thereof. In another aspect, the present disclosure refers to a microbial cell comprising an expression vector as described herein.

DETAILED DESCRIPTION

20 Hyperammonemia is a metabolic condition characterised by increased, or excess, ammonia in the blood. It is a dangerous condition, principally since it may lead to increased entry of ammonia to the brain, which in turn causes neurological disorders and neuropsychiatric abnormalities, which can be very severe, leading to, *inter alia*, brain damage, seizures, retardation, coma and even death. Indeed,
25 encephalopathy is a common and hazardous complication of hyperammonemia. Although precise mechanisms for encephalopathy/brain damage are not yet understood, astrocytic osmotic stress caused by the increased ammonia is believed to play a role, leading to cerebral oedema and increased intracranial pressure. Hyperammonemia may be congenital or acquired, and may be primary or
30 secondary.

Primary (congenital) hyperammonemia arises from various inborn errors of metabolism characterised by reduced activity of any of the enzymes or transporter proteins of the urea cycle. Indeed, such inborn errors of metabolism form a group of diseases called urea cycle disorders (UCD). Ammonia (NH_3), which may co-exist in
35 the body with its charged form ammonium (NH_4^+) depending on pH, is a product of the catabolism of proteins and other nitrogenous compounds. It is converted by the

enzymes of the urea cycle to the less toxic substance urea prior to excretion in urine by the kidneys. The urea cycle, which also functions as the sole source of production of certain amino acids (arginine, citrulline and ornithine) in the body, comprises 6 enzymes, the five catalytic enzymes carbamoyl phosphate synthetase I (CPS1), ornithinetranscarbamylase (OTC), or argininosuccinic acid synthetase 5 (ASS1), arginosuccinic acid lyase (ASL) and arginase (ARG), and the co-factor

producing enzyme N-acetylglutamate synthetase (NAGS) and 2 transporter proteins ornithine translocase (ORNT1) and citrin. A defect can occur in any one or more of these 8 proteins. Severe deficiency or total absence of activity of any of the first four enzymes or of NAGS result in accumulation of ammonia and other precursor metabolites during the first few days of life. Infants with a severe UCD are normal at birth but rapidly develop cerebral oedema and the related signs of lethargy, anorexia, hyper- or hypoventilation, hyperthermia, seizures, neurologic posturing and coma. Severity of the UCD is influenced by the position of the defective enzyme in the pathway and severity of the enzyme defect. With rapid identification and current treatment strategies, survival of neonates with hyperammonemia has improved dramatically in the last few decades, but intellectual ability is typically impaired. In milder, or partial, deficiencies of these enzymes and in ARG deficiency ammonia accumulation may be triggered by illness or stress at almost any time of life. In these disorders the elevations of plasma ammonia concentration and symptoms are often more subtle than the neonatal presentation of a UCD, and the first recognised clinical episode may not occur for months or decades.

Secondary hyperammonemia is caused by inborn errors of intermediary metabolism characterised by reduced activity in enzymes/proteins that are not part of the urea cycle, e.g. propionic acidaemia, methyl malonic acidaemia, galactosaemia, fatty acid oxidation disorders and mitochondrial disorders, or by dysfunction of cells (e.g. the liver) that make major contributions to ammonia metabolism and/or nitrogen metabolism more generally.

Acquired hyperammonemia is usually caused by liver diseases, including both acute and chronic liver failure, such as viral hepatitis or excessive alcohol consumption. Impaired liver function or vascular bypass of the liver, resulting in decreased filtration of blood in the liver, leads to hyperammonemia. Hepatic encephalopathy due to hyperammonemia is a common complication of liver disease.

Hyperammonemia may also occur for other reasons including renal dysfunction e.g. kidney dysfunction and/or failure, drug toxicity e.g. due to valproic acid or cyclophosphamide, idiopathic hyperammonemia syndrome after immunosuppression or cytotoxic therapy, ureolysis in stagnant urine and urinary tract infections, or essential amino acid total parenteral nutrition.

Current treatments for hyperammonemia are designed to reduce ammonia levels in the blood and/or the brain e.g. by haemodialysis (typically used in neonates) or by administering compounds that increase removal of nitrogen waste, for example non-absorbable disaccharides (e.g. lactulose) or antibiotics (e.g. rifaxamin) or compounds that convert nitrogen into products other than urea which are then excreted, e.g. compounds such as sodium benzoate, arginine, carglumic acid, phenylacetate or more latterly phenylbutyrate, or L-ornithine L-aspartate (LOLA) or L-ornithine phenylacetate (OP).

Management of the condition may also include dietary control to restrict protein intake and ensure adequate nutritional intake, including management of protein and/or nitrogen intake and parenteral intake of calories.

However, despite improvements in treatment and management of the condition current therapies are non-specific and do not always succeed in managing the condition successfully. In the case of UCD particularly, current therapies may not prevent many elevated ammonia events and patients with severe forms of the disease are often assessed for liver transplant around age 5. There is therefore a continuing need for further or improved therapies for hyperammonemia.

The present invention seeks to address this need and is based on the concept of using glutamine synthetase to detoxify ammonia by converting it to the non-toxic product glutamine. In particular, the present invention proposes systemically to administer glutamine synthetase as a protein therapy to reduce the levels of ammonia in the blood.

Glutamine synthetase (GS) catalyses the reaction:

Glutamate + ATP + NH₃ → Glutamine + ADP + phosphate.

Glutamine synthesis occurs in a number of organs of the body and may play a role in organ and whole-body nitrogen balance. Very recently, gene therapy based on overexpression of GS in the skeletal muscle has been proposed for the treatment of acute hyperammonemia (Torres-Vega et al, Gene Therapy 2015, 22, 58-64), the rationale for this therapy being to replace or augment GS which is generally deficient in the muscles of patients with liver disease, thereby aiming to increase the clearance of ammonia by this enzyme in the muscle. Gene therapy has however proved difficult to successfully administer in clinical practice and not all patients are suitable for it (e.g. children, with the exception of stem-cell based gene

therapies), or patients may be refractory to gene therapy (e.g. for immune reasons). Further, such a therapy would produce a mainly localised effect, in the muscle. Accordingly, a need still remains for a more generally applicable therapy.

Administration of GS systemically as a protein may serve to achieve such a more general effect. We have shown that GS, particularly human GS, may successfully be expressed and purified and may retain, or demonstrate, GS activity, both in unmodified and modified form, conjugated to a polymeric partner such as polyethylene glycol. Further, animal studies have shown that high circulating levels of the GS may be achieved by systemic administration and that both modified and unmodified GS administered to the animal retains activity in the blood and other tissues (e.g. liver). Thus, therapeutic levels of GS may be achieved by systemic (e.g. parenteral) administration of GS protein.

Additionally, the inventors have also surprisingly found that the combined use of a GS protein and an ammonia lowering agent (such as a nitrogen scavenger, for example, a pharmaceutically acceptable salt of phenylacetic acid, such as sodium phenylacetate) has a synergistic effect and may further increase the ability of the GS protein to treat or prevent hyperammonemia. Accordingly, in one aspect the present invention provides a glutamine synthetase (GS) protein for use in treating or preventing hyperammonemia by systemic non-oral administration to a subject.

In a suitable embodiment, the GS protein for use in treating or preventing hyperammonemia, may be for use in combination with an ammonia lowering agent.

In another aspect, the invention provides an ammonia lowering agent for use in combination with a GS protein, for use in treating or preventing hyperammonemia.

A related aspect of the invention also provides use of a GS protein for the manufacture of a composition (e.g. a pharmaceutical or nutritional composition, for example a medicament or supplement) for the treatment or prevention of hyperammonemia by systemic non-oral administration to a subject.

In a suitable embodiment, the composition may be for use in combination with an ammonia lowering agent.

A further aspect of the invention also provides use of an ammonia lowering agent for the manufacture of a composition for use in combination with a GS protein for the treatment or prevention of hyperammonemia.

In a further aspect the present invention provides use of a GS protein and an ammonia lowering agent for the manufacture of a composition for use in the treatment or prevention of hyperammonemia.

5 In a further aspect the present invention provides a method of treating or preventing hyperammonemia in a subject, said method comprising systemically and non-orally administering a GS protein to a said subject (more particularly to a subject in need thereof). In a suitable embodiment, the method further comprises administering an ammonia lowering agent.

10 Also provided is a composition comprising a GS protein, for use in treating or preventing hyperammonemia by systemic non-oral administration to a subject.

Suitably, the composition comprising a GS protein may be a pharmaceutical or nutritional composition, for example a medicament or supplement. Suitably, the composition may further comprise an ammonia lowering agent.

15 The invention also relates to a composition comprising an ammonia lowering agent, for use in treating or preventing hyperammonemia. Suitably, the composition comprising an ammonia lowering agent may be a pharmaceutical or nutritional composition, for example a medicament or supplement.

The invention also relates to a composition comprising a GS protein and an ammonia lowering agent.

20 Suitably the composition may be a pharmaceutical or nutritional composition. Suitably, the composition may be for use in treating or preventing hyperammonemia.

25 The term "GS protein" may alternatively be expressed as "a protein having glutamine synthetase (GS) activity". The term "protein" is used broadly herein to include any proteinaceous molecule, including peptides and polypeptides, as well as protein or polypeptide fragments; the GS protein does not have to be, or to correspond to, a full length GS enzyme as it appears in nature (e.g. a native or wild-type GS) and truncated or other variants are included, as described more detail below. Also included are conjugates, or fusions, of the GS protein with other
30 molecules, as also described in more detail below.

35 The term "hyperammonemia" includes any condition in which ammonia in the blood (or as measured or determined in any blood-derived product or sample e.g. blood plasma) is elevated as compared to the level of ammonia in a subject without the condition, e.g. a healthy subject or a subject without the underlying condition which leads to or causes the hyperammonemia. In health, ammonia

transport and metabolism are tightly regulated to maintain a low plasma/blood concentration (normal range 10-40 $\mu\text{mol/L}$). Thus, a plasma (or blood) ammonia concentration of > 40, 60 or 70 or 80 $\mu\text{mol/L}$ or more, e.g. 41, 42, 45, 50, 55, 60, 70 or 80 $\mu\text{mol/L}$ or more may be viewed as indicative of hyperammonemia. For
5 example, a plasma ammonia concentration of > 100 $\mu\text{mol/L}$, and particularly 150 $\mu\text{mol/L}$ or higher, where associated with a normal anion gap and a normal plasma glucose concentration, may be indicative of hyperammonemia, or more particularly, indicate the presence of a UCD.

Hyperammonemia may arise from any of the causes or conditions
10 discussed above, i.e. it may be congenital or acquired, primary or secondary, as discussed above. Thus, in one embodiment the hyperammonemia may arise due to (or be associated with) a urea cycle disorder (UCD). As discussed above, the UCD may arise from a defect in any one or more of the proteins of the urea cycle, which may inactivate or reduce the activity of the protein.

15 In a further embodiment the hyperammonemia may arise due to an inborn error of metabolism affecting a protein (e.g. enzyme) which is not part of the urea cycle, but which affects nitrogen metabolism and/or balance in the body, and leads to an increase in the amount of ammonia in the blood. Suitably, such an inborn error of metabolism may be glutamine synthetase deficiency.

20 In still further embodiments, the hyperammonemia may be acquired and may arise to disease or damage to an organ or tissue of the body which is involved in nitrogen metabolism and/or balance, for example in catabolism and/or excretion of nitrogen-containing molecules or substances e.g. the liver or kidney.

Thus any kind of liver damage or disease, including both chronic or acute
25 liver failure, for example liver damage due to excess alcohol consumption or due to drugs (whether recreational or medicinal), cirrhosis of the liver due to any cause, non-alcoholic fatty liver disease, infection of the liver or trauma to the liver may lead to hyperammonemia.

Similarly, any kind of damage to or disease of the kidney is described for the
30 liver above may also lead to hyperammonemia. Thus, any condition affecting multiple organs of the body (e.g. multiple organ failure) such as for example sepsis, organ damage from injury (whether external injury e.g. trauma, or internal injury e.g. from autoimmune disorders), or any systemic infection, may give rise to hyperammonemia.

- 7 -

Hyperammonemia may be detected or diagnosed based on clinical, biochemical and/or molecular genetic data, depending upon the underlying cause. Thus for example it may be detected by assessing or monitoring blood levels of ammonia (e.g. in plasma or serum or any blood-derived sample) according to techniques well known and used in the art. Analysis of amino acids present in the blood (plasma or serum, etc.) and/or the concentration thereof (for example arginine or citrulline) or other metabolites in the blood or other body fluids or tissues (e.g. orotic acid in urine) may also help to identify that a UCD is involved, and/or will determine the precise nature thereof (i.e. the specific protein/enzyme defect involved). Such determinations and analyses may be combined with clinical assessments, e.g. neurological and neuropsychiatric evaluations, including both physical (e.g. MRI or other imaging) and/or behavioural/response tests etc., liver and/or kidney or other organ function tests etc. In the case of a suspected UCD, investigations of family history and/or molecular genetic tests and/or assessments of enzyme activity of the urea cycle enzymes may also be undertaken.

As used herein, reference to a glutamine synthetase or GS protein for use according to the present invention includes reference to all forms of enzymatically-active GS, including human GS and GS from non-human animals (such as mouse, cow, rabbit, rat, monkey, chimpanzee, and dog etc), or from other sources including for example fungi, plants or bacteria, as well as enzymatically-active variants. Representative GS proteins thus include those having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the GS polypeptide set forth in SEQ ID NO:1 or 2 or 4 (human GS, precursor, mature and N-terminal tagged forms respectively) or with the GS polypeptide set forth in SEQ ID NO. 6 (GS from *Lactobacillus acididophilus* strain 30SC) or SEQ ID NO. 7 (GS from corn, *Zea Mays*), or an enzymatically-active fragment thereof. For example, reference to GS may also include N- and/or C-terminally truncated polypeptides or amino acid modified protein (eg. post-translational modifications, such as adenylation, or other modifications such as amino acid polymorphisms that may affect the structure or activity of the protein). It may also include multimers of the protein. The term "GS" thus includes all native forms of GS enzymes or polypeptides as well as enzymatically-active fragments or variants thereof, including synthetically derived and modified polypeptides having one or more amino acid substitutions, additions

(including insertions and extensions) or deletions, which retain GS enzymatic activity.

The GS may thus be, or may be derived from, any enzyme falling within the enzyme classification EC 6.3.1.2. It may be any polypeptide or peptide having GS activity. GS activity may be defined as the ability to convert glutamate and ammonia to glutamine, e.g. according to the reaction scheme set out above. GS activity may be assessed or determined using assays or tests (e.g. a functional activity assay) as known in the art and described in the literature. For example, GS enzyme activity assays are described in Listrom *et al*, Biochem. J. 1997, 328, 159-163. An assay for GS activity is also described in the Examples below (see Examples 2 and 4).

The term also includes a pro-drug for the GS, that is a form which does not in itself exhibit GS activity, but which may be converted to an active GS upon administration to the subject.

Thus, as used herein, "enzymatically-active" with reference to a GS protein or polypeptide refers to a GS protein or polypeptide that can catalyze the conversion of glutamate and ammonia to glutamine. Typically, the enzymatically-active GS protein or polypeptide exhibits at least or about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% of the enzymatic activity of a GS polypeptide as set forth in SEQ ID NO:1, 2, 4, 6 or 7.

The term "subject" as used herein includes any human or non-human animal and particularly refers to mammals, including for example humans, primates, livestock animals (e.g. sheep, pigs, cattle, horses, donkeys), laboratory test animals (eg. mice, rabbits, rats, guinea pigs), companion animals (eg. dogs, cats) and captive wild animals (eg. foxes, kangaroos, deer). Preferably, the mammal is human or a laboratory test animal. Even more preferably, the mammal is a human.

As used herein the terms "treating", "treatment", "preventing" and "prevention" refer to any and all uses which remedy or ameliorate a condition or symptoms, prevent the establishment of a condition or disease, or otherwise prevent, hinder, retard, reduce or reverse the progression of a condition or disease or other undesirable symptoms in any way whatsoever. Thus the terms "treating" and "preventing" and the like are to be considered in their broadest context. For example, treatment does not necessarily imply that a patient is treated until total recovery, but includes any improvement or amelioration in the condition of a patient or subject, or in a symptom of the disease or condition. Thus for example in the case of a UCD, treatment according to the present invention does not of course

treat the underlying genetic disorder, but rather the resulting clinical condition of hyperammonemia. In conditions which display or are characterized by multiple symptoms, the treatment or prevention need not necessarily remedy, ameliorate, prevent, hinder, retard, reduce or reverse all of said symptoms, but may remedy, ameliorate, prevent, hinder, retard, reduce or reverse one or more of said symptoms. In a suitable embodiment, "treatment" according to the present invention a reduction in the levels of ammonia in the blood, to for example normal or healthy levels, e.g. to the range 10-40 $\mu\text{mol/L}$. Thus, treatment includes the restoration of normal or healthy ammonia levels. Similarly, prevention according to the present invention may include maintenance of plasma/blood ammonia levels in any normal or healthy range, as indicated above.

In a suitable embodiment, "treatment" according to the present invention may include an increase in glutamine synthetase levels and/or activity in subject's tissue, to for example normal or healthy levels. Such an increase may be in any suitable tissue (for example liver and/or muscle). An increase in glutamine synthetase levels and/or activity may be, for example, determined by measuring levels of glutamine, levels of glutamate, and/or determining the ration between levels of glutamine and levels of glutamate, in a subject. It will be appreciated that normal or healthy levels of glutamine and/or glutamate may vary depending on the sample in which these are measured. It will also be appreciated that normal or healthy levels of glutamine and/or glutamate may be subject specific, and depend on factors such as the subject's weight, diet, sex and age. Normal or healthy levels of glutamine and/or glutamate will be known to those skilled in the art.

In a suitable embodiment "treatment" according to the present invention may include a reduction in oedema. The term "oedema" as used herein refers to abnormal accumulation of serous fluid in the subject. In a suitable embodiment, oedema may be brain oedema, pulmonary oedema, peripheral oedema, and/or macular oedema. Suitably, in the context of the present invention, "treatment" may refer to a reduction in brain oedema, for example in the prefrontal cortex. By way of example, oedema may be assessed by a CT scan, MRI, and/or an x-ray. Other methods of assessing oedema will be known to those skilled in the art.

In a suitable embodiment "treatment" according to the present invention may include an improvement in neuropsychological, neuropsychiatric and neurocognitive function. The term "neuropsychological, neuropsychiatric and neurocognitive function" refers to the function of the brain which controls, for example, memory,

attention, cognition, psychomotor activity, coordination and mood. Uses, methods and compositions of the invention which involve the combination of a GS protein and an ammonia lowering agent may be particularly useful in such an embodiment. Various methods for assessing neural function will be known to those skilled in the art. The neuronal functional status may be assessed using electroencephalography, computerised tests, paper and pencil tests and assessments by a neuropsychologist.

In a suitable embodiment "treatment" according to the present invention may include an improvement in sarcopenia and physical function. The term "sarcopenia" refers to reduced muscle mass. The term "physical function" refers to the subject's strength, in particular muscle strength. The severity of sarcopenia may be determined by using clinical tools, nutritional tools, measurement of body composition or imaging. Physical function may be assessed, for example, by assessment of oxygen delivery and consumption, exercise test and hand-grip test, and/or an improvement in levels of fatigue, and/or immune system function.

As used herein, "amelioration" refers to the lessening of severity of at least one indicator or symptom of a condition or disease. In certain embodiments, amelioration includes a delay or slowing in the progression of one or more indicators of a condition or disease. The severity of indicators may be determined by subjective or objective measures, which are known to those skilled in the art.

As used herein the term "associated with" when used in the context of a disease or condition "associated with" the elevated levels of ammonia means that the disease or condition may result from, result in, be characterised by, or otherwise associated with the elevated levels of ammonia. Thus, the association between the disease or condition and the elevated levels of ammonia may be direct or indirect and may be temporally separated.

Appropriate samples for determination of levels of ammonia include any appropriate or desired sample in which the ammonia may occur. By the same token, appropriate samples for determination of glutamine synthetase levels and/or glutamine synthetase activity, include any appropriate or desired sample in which glutamine synthetase, glutamine and/or glutamate may be present. These may be any appropriate or desired tissue or body fluid sample. An example of a suitable tissue is liver and/or muscle tissue. Conveniently, a sample may be any body fluid sample, and typically will be blood or any blood-derived sample e.g. plasma or serum etc, but it may be any other body fluid e.g. urine, cerebrospinal fluid, or a

stool or tissue sample etc, for example a biopsy sample or a lavage or washing fluid sample etc. This may depend of course on the precise nature of the condition to be treated etc.

5 As used herein the term "effective amount" includes within its meaning a non-toxic but sufficient amount or dose of, depending on the context, GS protein and/or an ammonia lowering agent, to provide the desired effect. It will be appreciated that the effective amount of the protein and/or the ammonia lowering agent may be different. Exemplary therapeutically effective amounts are specified elsewhere in this specification.

10 The exact amount or dose required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular FMO3 being administered and the mode of administration and so forth. Thus, it is not appropriate to specify an exact "effective amount". However, for any given
15 case, an appropriate "effective amount" may be determined by one of ordinary skill in the art using only routine experimentation.

Human GS is expressed as a polypeptide of 373 amino acids (as shown in SEQ ID NO. 1). This represents the full "precursor" protein as expressed which is then further processed to a mature form having amino acids 2-373 (only the N-
20 terminal methionine is removed to yield a mature protein of 372 amino acids *in vivo*, as shown in SEQ ID NO. 2. The exemplary polynucleotide set forth in SEQ ID NO.3 represents a cDNA encoding the polypeptide of SEQ ID NO. 1. SEQ ID NO. 4 represents a modified human GS protein, comprising the GS polypeptide of SEQ ID NO. 1 provided with an N-terminal His-tag and linker sequence, as prepared and
25 used in the Examples below. SEQ ID NO. 5 is a cDNA sequence encoding the polypeptide of SEQ ID NO. 4, codon-optimised for expression in bacteria, as used in the Examples below.

Human GS has been well-characterised (see for example Listrom *et al.*, 1997, *supra*). GS enzymes from other organisms, including plants and bacteria,
30 have also been identified, and nucleic acid and amino acid sequences of such other GS enzymes are well known in the art and provided in freely-available databases, such as, for example, the National Center for Biotechnology Information (NCBI) Nucleotide (ncbi.nlm.nih.gov/nuccore) and Protein (ncbi.nlm.nih.gov/protein)
databases. Although the sequence identity between plant or bacterial GS enzymes
35 and human GS may be low, the structural and functional similarity is high.

Accordingly, plant or bacterial GS, or indeed GS from other organisms, or amino acid sequence variants thereof, may be used. By way of representative example, SEQ ID NO.6 sets forth the amino acid sequence of the GS from *Lactobacillus acidophilus* strain 30SC, which has 23.8% sequence identity with human GS and
5 61.9% sequence identity with the GS of *Lactobacillus casei*, and SEQ ID NO. 7 sets forth the amino acid sequence of the GS from corn (maize, *Zea Mays*), which has 55.7% sequence identity with human GS.

GS commonly occurs as a multimer comprising multiple (i.e. 2 or more) monomer subunits. The GS amino acid sequence provided above, for example,
10 represents such a monomer subunit. Human GS is most frequently reported as a dodecamer (12 subunits). As used herein, the GS may be provided as a monomer and/or as a multimer. The multimer may comprise 2 or more monomer subunits, for example 2 to 20, 2 to 16, 2 to 15, 2 to 14 or 2 to 12 subunits.

Indeed, a surprising feature of the present invention is that contrary to the
15 reports in the literature of a 12-subunit multimer, human GS may be expressed and/or obtained as a mixture of multiple different types of multimer, including also a monomeric form. The monomeric form has been shown to be active. Thus, according to the present invention, the GS may be used as a monomer and/or as a multimer, and the multimer may be provided as a single multimeric form, or as a
20 mixture of different multimeric forms which may or may not include the monomer. As reported in the examples below, 4 or more, e.g. 4 to 10, e.g. 5 to 8 multimeric forms may be obtained. The multimers may range in size from 2 to 20 subunits.

The GS protein used in the methods provided herein can be obtained by any method known in art, such as recombinant methods, protein isolation and
25 purification methods and chemical synthesis methods, providing the resulting GS exhibits enzymatic activity. Accordingly, the GS can be recombinant GS, native GS isolated from tissue, or chemically synthesised GS.

It is well within the capabilities of a skilled person to modify a GS polypeptide, such as the polypeptide set forth in SEQ ID NO:1, to generate
30 enzymatically-active GS variants for use in the methods provided herein. For example, a person skilled in the art would understand that modifications at positions involved in substrate binding, or in the active site, are less likely to be tolerated than modifications at positions outside these critical regions. Any GS polypeptide can be tested using methods well known in the art, such as those described in the
35 Examples below, to assess the ability of the GS polypeptide to catalyze the

conversion of glutamate and ammonia to glutamine.

In some examples, the GS used according to the invention herein is recombinant GS produced using prokaryotic or eukaryotic expression systems well known in the art. Exemplary prokaryotic expression systems include, but are not limited to, *Escherichia coli* expression systems, and exemplary eukaryotic expression systems include, but are not limited to, yeast, insect cell and mammalian cell expression systems.

Nucleic acid encoding GS can be obtained by any suitable method, including, but not limited to, RT-PCR of liver RNA and synthetic nucleotide synthesis. Primers for amplification can be designed based on known GS sequences, such as that set forth above. Nucleic acid and amino acid sequences of GS are well known in the art and provided in freely-available databases, such as, for example, the National Center for Biotechnology Information (NCBI) Nucleotide (ncbi.nlm.nih.gov/nuccore) and Protein (ncbi.nlm.nih.gov/protein) databases.

Nucleic acid encoding the GS polypeptide, such as nucleic acid having a sequence set forth in SEQ ID NO.3, can be cloned into an expression vector suitable for the expression system of choice. In some instances, the nucleic acid is codon-optimized for expression in a particular system. For example, the nucleic acid encoding the GS polypeptide can be codon-optimised for expression in *E. coli*. An exemplary codon-optimised nucleic acid encoding GS for expression in *E. coli* is set forth in SEQ ID NO 5, which encodes a GS polypeptide comprising a His-tag attached via a GGGGS linker (as set forth in SEQ ID NO.4).

Typically the nucleic acid encoding the GS is cloned into an expression vector, operably linked to regulatory sequences that facilitate expression of the heterologous nucleic acid molecule. Many expression vectors suitable for the expression of GS are available and known to those of skill in the art. The choice of expression vector is influenced by the choice of host expression system. Such selection is well within the level of skill of the skilled artisan. In general, expression vectors can include transcriptional promoters and optionally enhancers, translational signals, and transcriptional and translational termination signals. Expression vectors that are used for stable transformation typically have a selectable marker which allows selection and maintenance of the transformed cells. In some cases, an origin of replication can be used to amplify the copy number of the vectors in the cells.

GS polypeptides also can be expressed as protein fusions. For example, a

fusion can be generated to add additional functionality to a polypeptide. Examples of fusion proteins include, but are not limited to, fusions containing GS and an affinity tag for purification (e.g. a his-tag e.g. his6, MYC, FLAG, HA or GST tag), a leader sequence (such as the pelB leader sequence), a sequence for directing protein secretion, or a protein for stabilising and/or solubilising GS (e.g. maltose-binding protein (MBP)), or a protein for increasing *in vivo* half-life (e.g. albumin or Fc domains, or fragments thereof).

Prokaryotes, especially *E. coli*, provide a system for producing large amounts of GS. Transformation of *E. coli* is a simple and rapid technique well known to those of skill in the art. Expression vectors for *E. coli* can contain inducible promoters that are useful for inducing high levels of protein expression and for expressing proteins that exhibit some toxicity to the host cells. Examples of inducible promoters include the lac promoter, the trp promoter, the hybrid tac promoter, the T7 and SP6 RNA promoters and the temperature regulated λ PL promoter.

In other examples, eukaryotic expression systems are used to produce the GS, such as baculovirus expression systems. Typically, expression vectors use a promoter such as the polyhedrin promoter of baculovirus for high level expression. Commonly used baculovirus systems include baculoviruses such as *Autographa californica* nuclear polyhedrosis virus (AcNPV), and the *Bombyx mori* nuclear polyhedrosis virus (BmNPV) and an insect cell line such as Sf9 derived from *Spodoptera frugiperda*, *Pseudaletia unipuncta* (A7S) and *Danaus plexippus* (DpNI). For high level expression, the nucleotide sequence of the GS is fused immediately downstream of the polyhedrin initiation codon of the virus.

Yeasts such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Yarrowia lipolytica*, *Kluyveromyces lactis*, and *Pichia pastoris* can also be used expression hosts for GS. Yeast can be transformed with episomal replicating vectors or by stable chromosomal integration by homologous recombination. Typically, inducible promoters, such as include GAL1, GAL7, and GAL5, are used to regulate gene expression. Yeast expression vectors often include a selectable marker such as LEU2, TRP1, HIS3, and URA3 for selection and maintenance of the transformed DNA.

Mammalian expression systems also can be used to express GS. Expression constructs can be transferred to mammalian cells by viral infection such as adenovirus or by direct DNA transfer such as liposomes, calcium phosphate,

DEAE-dextran and by physical means such as electroporation and microinjection. Expression vectors for mammalian cells typically include an mRNA cap site, a TATA box, a translational initiation sequence (Kozak consensus sequence) and polyadenylation elements. Such vectors often include transcriptional promoter-enhancers for high level expression, for example the SV40 promoter-enhancer, the human cytomegalovirus (CMV) promoter, and the long terminal repeat of Rous sarcoma virus (RSV). Exemplary cell lines available for mammalian expression include, but are not limited to, mouse, rat, human, monkey, and chicken and hamster cells, such as BHK, 293-F, CHO, Balb/3T3, HeLa, MT2, mouse NSO (non-secreting) and other myeloma cell lines, hybridoma and heterohybridoma cell lines, lymphocytes, fibroblasts, Sp2/0, COS, NIH3T3, HEK293, 293S, 293T, 2B8, and HKB cells.

Following expression, GS can be purified using any method known to those of skill in the art including, but not limited to, SDS-PAGE, size fraction and size exclusion chromatography, ammonium sulfate precipitation, chelate chromatography, ionic exchange chromatography and affinity chromatography. Affinity purification techniques can be used to improve the efficiency and purity of the preparations. For example, antibodies and other molecules that bind GS can be used in affinity purification. As discussed above, expression constructs can be engineered to add an affinity tag such as a his, myc, FLAG or HA tag or GST moiety to GS, which can then be affinity purified with Ni-resin, myc antibody, HA antibody, FLAG antibody or glutathione resin, respectively. Purity can be assessed by any method known in the art including gel electrophoresis and staining and spectrophotometric techniques, such as SDS page and Size Exclusion Chromatography (SEC).

For use according to the present invention, the affinity tag (e.g. his tag etc) may be removed, but this is not necessary, and the GS polypeptide may be used with the tag attached.

The tag or other fusion partner may be attached to the GS via a linker, which may be any suitable linker, according to principles well known in the art. Such a linker may typically and conveniently be a short (e.g. 2 to 10, 2 to 8 or 2-6 mer) peptide. By way of example the linker GGSG may be mentioned, but could be made up of any suitable amino acids. Amino acid linkers enable preparation of the fusion protein by recombinant means but non-amino acid-based linkers might also be used, again according to principles and techniques well known in the art and

described in the literature. The linker may be cleavable (e.g. enzymatically) or non-cleavable.

GS polypeptides can be prepared as naked polypeptide chains or as modified polypeptides which are modified by coupling or conjugating to a further moiety or chemical group or substance. Exemplary modifications include, but are not limited to, pegylation, albumination or other known modifications. For example, in some instances, the GS polypeptides for use in the described methods are pegylated using standard methods well known in the art. This may serve, for example, to improve the half-life of the GS protein in the circulation. Thus, in a preferred embodiment of the invention the GS protein may be provided as a conjugate with a polymer such as polyethylene glycol (PEG) or a poly- or oligosaccharide. Conjugates with PEG are particularly preferred. As indicated above the preparation of such conjugates is well known in the art and described in the literature. Thus, PEGs of various sizes may be used to prepare the conjugates e.g. ranging from 100 Daltons to 100 kD, but more often from 5kD to 100 kD, for example 12 or 15 kD to 60 or 80 kD, such as 15 to 50, 15 to 40, or 15 to 30 kD. Further, the PEG may be attached or linked to the GS protein in various ways, and more than one PEG may be attached to each single protein. It may be linked directly or indirectly, e.g. via a linker as described, for fusion proteins above or by any molecular or chemical group which may provide a linker function. Thus, the PEG may be linked at one or both of the N- or C- termini, or internally in the GS molecule, for example at the amino group of one or more lysine residues in the GS protein molecule or at any other chemical moiety or residue in the protein molecule. Methods for coupling or conjugating polymers such as PEG to proteins are well known in the art and described in the literature (see for example Roberts *et al.* 2012, Advanced Drug Delivery Reviews, 64 (supplement) 116-127 and Veronese 2001, Biomaterials 22, 405-417). The data presented in the Examples below shows that PEG conjugates prepared by linking the PEG to the N-terminal are especially effective, for example in activity assays of liver lysates from animals administered various conjugates. Accordingly, a PEG conjugate comprising a PEG linked to the N terminus of a GS protein represents one preferred embodiment of the present invention. The GS protein may be pegylated in monomeric and/or multimeric form. Thus, for convenience a preparation comprising both monomeric and various multimeric forms of GS may be subjected to pegylation.

GS can be formulated as a pharmaceutical composition for administration to

a subject. GS can be formulated in any conventional manner by mixing a selected amount of GS with one or more physiologically or pharmaceutically acceptable carriers or excipients.

5 Accordingly, a further aspect of the invention provides a pharmaceutical composition comprising a GS protein and one or more pharmaceutically-acceptable carriers or excipients, wherein the composition is for non-oral systemic administration.

10 Selection of the carrier or excipient is within the skill of the administering profession and can depend upon a number of parameters, such as the mode of administration. In some examples the GS is provided as a fluid. In other instances, the GS is provided in dried form, such as desiccated or freeze-dried form. Such dried forms can be rehydrated prior to administration by the addition of a suitable solution, such as water, buffer, saline or other suitable solution. The GS provided
15 herein can be formulated for direct administration or can be formulated for dilution or other modification. Accordingly, the GS can be formulated in single (or unit) dosage forms or multiple dosage forms. Examples of single dose forms include ampoules and syringes. Examples of multiple dose forms include vials and bottles that contain multiple unit doses.

20 The concentrations of the GS in the formulations are effective for delivery of an amount of GS that, upon administration, is effective to convert ammonia to glutamine in the presence of glutamate. The concentrations and amounts will depend on several factors, including the levels of the substrates in the subject, and mode of administration, and can be empirically determined. Exemplary concentrations of GS in the compositions provided herein include, but are not
25 limited to, concentrations of or about 0.1, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 1000, 2000, 3000, 4000 or 5000 mg/mL GS or more.

30 To formulate the GS composition, in one embodiment the weight fraction of GS is dissolved, suspended, dispersed, or otherwise mixed in a selected vehicle at the desired concentration. The resulting mixtures are solutions, suspensions, emulsions and other such mixtures, and can be formulated as a non-aqueous or aqueous mixture, including but not limited to, a solution, suspension, paste, gel, aerosol, spray, or any other formulation suitable for systemic administration.

35 Generally, the GS composition is prepared in view of approval from a regulatory agency or otherwise prepared in accordance with generally recognized

pharmacopeia for use in animals and in humans. The GS composition can include carriers such as a diluent, excipient, or vehicle. Such pharmaceutical carriers can be sterile liquids, such as water and oils. Saline solutions and aqueous dextrose and glycerol solutions also can be employed as liquid carriers, particularly for injectable solutions. Compositions can contain along with an active ingredient: a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polyvinylpyrrolidone, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, and ethanol. A GS composition, if desired, also can contain minor amounts of wetting or emulsifying agents, or pH buffering agents, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin.

Liposomal suspensions, including tissue-targeted liposomes, can also be suitable as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art. Liposomal delivery can also include slow release formulations, including pharmaceutical matrices such as collagen gels and liposomes modified with fibronectin.

As well as in pharmaceutical compositions, the GS may also be formulated or administered in other ways, for example in a nutritional composition such as a dietary supplement, for example a parenteral nutrition composition (e.g. alone or alongside other supplement ingredients). It may be included in such foods as a polypeptide (e.g. purified enzyme) or as part of an expressing host cell or organism. Thus for example microbial (e.g. yeast or bacterial or fungal) host cells or plants (including plants cells) may be engineered to express GS and may be administered as such, e.g. a whole cells or extracts or other processed products (in which enzymatic activity may be retained), or may be incorporated into nutritional compositions. Thus, for example, bacterial or yeast cells suitable for human or non-human animal consumption may be engineered to express GS (namely by introduction of a nucleic acid molecule comprising a nucleotide sequence encoding

GS). Alternatively, plants may be engineered in an analagous manner and appropriate plant parts etc (e.g. seeds, leaves, tubers etc) may be provided for administration. It is known in the art which microorganisms (yeasts, bacteria, algae or fungi for example) are suitable for human or other animal consumption and many such organisms are used today, for example in probiotic formulations. Any such probiotic organisms or formulations could be used e.g. based on lactic acid bacteria such as *Bifidobacterium* or *Lactobacillus* sp. (e.g. *L. acidophilus*) etc. Thus, according to the present invention such organisms or preparations may be formulated for and administered directly into the GI tract, e.g. by injection or infusion, or enema or rectal administration etc. The precise amount or dose of the GS administered to the subject depends on the activity of the GS, the route of administration, the disease or condition being treated, the number of dosages administered, and other considerations, such as the weight, age and general state of the subject. Particular dosages and administration protocols can be empirically determined or extrapolated from, for example, studies in animal models. Exemplary therapeutically effective doses of the GS include, but are not limited to, from or from about 0.1 µg/kg body weight per day to or to about 10000 µg/kg body weight per day, including from or from about 1 µg/kg to or to about 1000 µg/kg body weight per day, or from or from about 10 µg/kg to or to about 100 µg/kg body weight per day. Thus, for example, a subject can be administered 0.1, 0.2, 0.3, 0.4, 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 400, 600, 800, 1000, 2000, 4000, 6000, 8000, 10000, or 20000 µg or more the GS per kg body weight per day.

It is a feature of the present invention that the GS is administered systemically, but non-orally. By "orally" it is meant per-oral delivery. Accordingly, non-oral means that the GS protein is not administered by ingestion via the mouth. Although other means of administration which deliver the GS protein to the intestines or more generally the gastrointestinal (GI) tract may be included (e.g. rectally, or by enema, or direct administration into the GI tract), in certain embodiments they are excluded. Accordingly, in a certain embodiment the invention includes enteral administration, but in another embodiment it does not. In a further embodiment the invention does not include administration to the muscle, particularly to skeletal muscle. Thus, in such an embodiment the administration is not directed to muscle, i.e. is a non-muscle directed therapy.

Accordingly the GS can be administered by any method and route that delivers the GS protein systemically to the body, but does not involve oral

administration. In certain embodiments the GS protein may be administered parenterally. A skilled artisan would readily understand and be able to select appropriate modes of administration or delivery, including, but not limited to, intravenous, intramuscular, intradermal, transdermal, subcutaneous, or intraperitoneal administration, as well as by any combination of any two or more thereof, formulated in a manner suitable for each route of administration. In some instances, the GS compositions described herein are administered subcutaneously. In other instances the GS compositions may be administered intravenously. For example, the GS compositions can be administered intravenously by injection or infusion, such as by an intravenous bolus.

The GS protein may also be administered in conjunction or combination with other therapeutic or active agents, notably a second or further therapeutic agent which may treat (e.g. to improve) hyperammonemia. A second or further therapeutic agent which is active to treat hyperammonemia may be alternatively defined as an anti-hyperammonemia agent or as an agent against hyperammonemia. The second or further agent may typically be an ammonia lowering agent such as a nitrogen scavenger (or an ammonia scavenger) or a replacement amino acid or urea cycle intermediate, or an analogue thereof. Such an agent may therefore include an amino acid, for example arginine, glutamate, citrulline and/or ornithine, and/or N-acetyl glutamate and/or the analogue molecule carbamyl glutamate (Carbaglu®). More suitably, the second or further agent is an ammonia lowering agent, more suitably a nitrogen scavenger. Such an embodiment gives rise to certain aspects of the present invention.

The term "ammonia lowering agent" refers to a compound which removes ammonia and/or reduces, or inhibits ammonia production. An ammonia lowering agent may be selected from the group consisting of a nitrogen scavenger, an ion exchange resin (for example Relapsa), an ammonia absorber (such as a liposomal based ammonia absorber, for example Versantis), an engineered microbiome that removes ammonia (for example Synlogic), Rifaximin and Lactulose.

The term "nitrogen scavenger" as used herein, refers to a compound which reduces the levels of nitrogen and/or ammonia in a subject by removing ammonia. In a suitable embodiment the nitrogen scavenger reduces the amount of nitrogen and/or ammonia in the subject by being metabolised to phenylacetyl glutamine, which may be then excreted in urine.

In a suitable embodiment, a nitrogen scavenger may be selected from the group consisting of a pharmaceutically acceptable salt of phenylacetic acid (also referred to herein as phenylacetate), a pharmaceutically acceptable salt of phenylbutyric acid (also referred to herein as phenylbutyrate), glycerol phenylbutyrate, a pharmaceutically acceptable salt of benzoic acid, a
5 pharmaceutically acceptable pro-drug thereof, and ammonia binding resin. Other nitrogen scavengers will be well known to those skilled in the art.

As used herein, the term "pharmaceutically-acceptable salt" includes, for example, an acid-addition salt of phenylacetic acid which is sufficiently basic, for
10 example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane sulfonate or maleic acid. In addition, a suitable pharmaceutically acceptable salt of phenylacetic acid which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for
15 example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

In a suitable embodiment, a pharmaceutically acceptable salt of
20 phenylacetic acid may be selected from the group consisting of sodium phenylacetate, potassium phenylacetate, ornithine phenylacetate.

In a suitable embodiment, a pharmaceutically acceptable salt of phenylbutyric acid may be selected from the group consisting of sodium phenylbutyrate and potassium phenylacetate.

25 In a suitable embodiment, a pharmaceutically acceptable salt of benzoic acid may be selected from the group consisting of sodium benzoate and potassium benzoate.

It shall be understood that an ammonia lowering agent may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be
30 understood that in the context of the present invention encompassed are all such solvated and unsolvated forms.

The term "pro-drug" as used herein refers to an agent rendered less active by a chemical or biological moiety than the ammonia lowering agent (such as nitrogen scavenger), but which metabolises into or undergoes *in vivo* hydrolysis to
35 form the ammonia lowering agent.

In particular, agents such as phenylacetate or phenylbutyrate compounds are preferred, which act to remove glutamine from the circulation (glutamine being formed by the action of GS). The second or further agent, such as an ammonia lowering agent, may be administered separately, sequentially or simultaneously with the GS protein, including in the same formulation or composition, or in a separate composition or formulation.

Accordingly, in a further aspect, the invention provides a product comprising a GS protein for systemic non-oral administration and a further therapeutic agent, as a combined preparation for separate, simultaneous or sequential use in treating or preventing hyperammonemia.

The second or further agent may be administered by the same administration route or by a different administration route, including orally. Thus, in one exemplary embodiment the second or further, such as an ammonia lowering agent, agent may be administered orally, or by other systemic means and the GS may be administered by non-oral systemic means.

Ammonia lowering agents, such as nitrogen scavengers (including sodium phenylacetate, ornithine phenylacetate, sodium phenyl butyrate, or sodium benzoate) may be administered by intravenous infusion e.g. for acute management, and/or orally, e.g for long-term maintenance. The i.v. infusion may be peripheral but central i.v. infusion is preferred. Similarly amino acids such as arginine may be administered orally or i.v., for example by central i.v. infusion.

Accordingly, a yet further aspect of the present invention provides a product (e.g. a combination product) comprising a GS protein for systemic non-oral administration and a further therapeutic agent as a combined preparation for separate, simultaneous or sequential use in treating or preventing hyperammonemia. In a suitable embodiment, such a further therapeutic agent may be an ammonia lowering agent. More suitably the ammonia lowering agent may be a nitrogen scavenger. More suitably, the nitrogen scavenger may be a pharmaceutically acceptable salt of phenylacetic acid, more suitably sodium phenylacetate.

Alternatively viewed, this aspect of the invention also provides a kit comprising (a) a GS protein for systemic non-oral administration and (b) a further therapeutic agent. Suitably, the further therapeutic may be effective against hyperammonemia. Suitably, the further therapeutic agent is an ammonia lowering agent, more suitably a nitrogen scavenger.

Accordingly, in a further aspect the invention provides a kit comprising (a) a GS protein for systemic non-oral administration and (b) a nitrogen scavenger. Suitably, the nitrogen scavenger may be a pharmaceutically acceptable salt of phenylacetic acid, more suitably sodium phenylacetate.

5 Such kits may be provided for use in treating or preventing hyperammonemia. The components of the kit may be provided as separate pharmaceutical compositions comprising the agent(s) in question together with one or more pharmaceutically-acceptable carriers or excipients. The composition(s) of the invention can be administered once or more than once. If the composition(s)
10 are administered more than one time, they can be administered at regular intervals or as needed, for example as determined by a clinician. Regular intervals can include, for example, approximately daily, weekly, bi-weekly, monthly, or any other interval. Selecting a treatment protocol is well within the level of skill of the skilled artisan. For example, a protocol can be determined based upon studies in animal
15 models. In other example, repeat doses of the composition(s) can be administered to a subject if the ammonia level in the blood, is above a predetermined level.

The use of the GS protein, or the use of the ammonia lowering agent in combination with a GS protein, according to the present invention is advantageous for the treatment of subjects for whom gene therapy is not suitable or appropriate,
20 for example children or subjects who are refractory to gene therapy. Such refractory subjects may include for example those who have previously been exposed to, or have had an immune reaction to, the viral vector used for delivery of the gene therapy.

Advantageously, the use of a protein as the therapeutic agent allows higher
25 doses of the active protein to be delivered to the subject and for doses to be adjusted according to subject and to need. Furthermore, as compared to gene therapy, protein therapy allows for a much faster response, and hence is more suitable for emergency use.

As mentioned, one aspect of the invention relates to a pharmaceutical
30 composition comprising an ammonia lowering agent, for use in combination with GS protein for use in treating or preventing hyperammonemia. The ammonia lowering agent can be formulated as a pharmaceutical composition for administration to a subject. The ammonia lowering agent, can be formulated in any conventional manner by mixing a selected amount of the nitrogen scavenger, with
35 one or more physiologically or pharmaceutically acceptable carriers or excipients.

Suitably, the composition may be for non-oral systemic administration, or oral administration. It will be appreciated that the pharmaceutical composition may also comprise GS protein. In such an embodiment, the composition will be formulated for non-oral systemic administration.

5 Selection of the carrier or excipient is within the skill of the administering profession and can depend upon a number of parameters, such as the mode of administration. In some examples the ammonia lowering agent, is provided as a fluid. In other instances, the ammonia lowering agent, is provided in dried form. Such a dried form can be rehydrated prior to administration by the addition of a
10 suitable solution, such as water, buffer, saline or other suitable solution. The ammonia lowering agent can be formulated for direct administration or can be formulated for dilution or other modification. Accordingly, the ammonia lowering agent can be formulated in single (or unit) dosage forms or multiple dosage forms. Examples of single dose forms include ampoules and syringes. Examples of
15 multiple dose forms include vials and bottles that contain multiple unit doses.

 The concentrations of the ammonia lowering agent in the formulations are effective for delivery of an amount of ammonia lowering agent that, upon administration, is effective to remove nitrogen and/or ammonium from the circulation, or reduce or inhibit ammonia production. The concentrations and
20 amounts will depend on several factors, including the levels of the substrates in the subject, and mode of administration, and can be empirically determined. Exemplary concentrations of the ammonia lowering agent in the compositions provided herein include, but are not limited to, concentrations of or about 0.1, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400,
25 500, 1000, 2000, 3000, 4000 or 5000 mg/mL of ammonia lowering agent or more.

 To formulate the ammonia lowering agent composition, in one embodiment the weight fraction the ammonia lowering agent is dissolved, suspended, dispersed, or otherwise mixed in a selected vehicle at the desired concentration. The resulting mixtures are solutions, suspensions, emulsions and other such mixtures, and can
30 be formulated as a non-aqueous or aqueous mixture, including but not limited to, a solution, suspension, paste, gel, aerosol, spray, or any other formulation suitable for systemic administration.

 Generally, the ammonia lowering agent is prepared in view of approval from a regulatory agency or otherwise prepared in accordance with generally recognized
35 pharmacopeia for use in animals and in humans. The composition can include

carriers such as a diluent, excipient, or vehicle. Such pharmaceutical carriers can be sterile liquids, such as water and oils. Saline solutions and aqueous dextrose and glycerol solutions also can be employed as liquid carriers, particularly for injectable solutions. Compositions can contain along with an active ingredient: a
5 diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polvinylpyrrolidone, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art. Suitable pharmaceutical
10 excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, and ethanol. A phenylacetic acid, or a pharmaceutically acceptable salt thereof composition, if desired, also can contain minor amounts of wetting or emulsifying agents, or pH buffering agents, for
15 example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents. Other examples of suitable pharmaceutical carriers will be known to those skilled in the art.

The ammonia lowering agent can be administered by any method and route
20 that delivers the compound to the body. In certain embodiments, the ammonia lowering agent can be administered parenterally. A skilled artisan would readily understand and be able to select appropriate modes of administration or delivery, including, but not limited to, oral, intravenous, intramuscular, intradermal, transdermal, subcutaneous, or intraperitoneal administration, as well as by any
25 combination of any two or more thereof, formulated in a manner suitable for each route of administration.

As well as in pharmaceutical compositions, the ammonia lowering agent may also be formulated or administered in other ways, for example in a nutritional composition such as a dietary supplement, for example a parenteral nutrition
30 composition (e.g. alone or alongside other supplement ingredients). Suitably, such a composition may be for oral or non-oral administration.

As mentioned, the ammonia lowering agent is for administration in combination with GS protein. It will be appreciated that the ammonia lowering agent may be administered separately, sequentially or simultaneously with the GS
35 protein, including in the same formulation or composition, or in a separate

composition or formulation. Thus, in one exemplary embodiment the ammonia lowering agent may be administered orally, or by other systemic means and the GS may be administered by non-oral systemic means.

Exemplary therapeutically effective doses of the ammonia lowering agent, include but are not limited to, from about 1 mg/kg body weight per day to or to about 2000 mg/kg body weight per day, including from or from about 10 mg/kg to or to about 1000 mg/kg body weight per day, or from or from about 100 mg/kg to or to about 500 mg/kg body weight per day. Thus, for example, a subject can be administered 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, or 2000 mg or more of the ammonia lowering agent per kg body weight per day. Other exemplary therapeutically effective doses of the ammonia lowering agent, include but are not limited to, from about 1 g/day to about 50 g/day. Thus, for example, a subject can be administered 1, 2, 3, 4, 5, 10, 20, 30, 40, or 50 grams, or more of the ammonia lowering agent per day. It will be appreciated that the effective dose may vary depending on the ammonia lowering agent. The GS composition, and/or the composition comprising the ammonia lowering agent or composition comprising a further agent which is not an ammonia lowering agent, if desired, can be presented in a package, in a kit or dispenser device, such as a syringe with a needle, or a vial and a syringe with a needle, which can contain one or more unit dosage forms. The kit or dispenser device can be accompanied by instructions for administration. In an embodiment where the GS composition and the composition comprising the ammonia lowering agent are separate, the kit may comprise the GS composition and the composition comprising the ammonia lowering agent. Suitably, in such an embodiment, the kit may comprise a GS composition, and a nitrogen scavenger. Suitably, in such an embodiment, the kit may comprise a GS composition, and a composition comprising phenylacetate, for example sodium phenylacetate. The compositions can be packaged as articles of manufacture containing packaging material, the composition, and a label that indicates that the composition is for administration to subjects for the treatment of hyperammonemia or a disease or condition associated with hyperammonemia.

In a further aspect, the invention provides an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for use in the treatment or prevention of hyperammonemia, wherein the vector is for systemic administration.

In a suitable embodiment, the vector further encodes an ammonia lowering agent.

In another aspect, the invention provides an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for use in combination with an ammonia lowering agent, for use in the treatment or prevention of hyperammonemia.

In another aspect, the invention provides an ammonia lowering agent for use in combination with an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for use in the treatment or prevention of hyperammonemia.

In another aspect, the invention provides a cell comprising an expression vector selected from the group consisting of: an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for use in the treatment of hyperammonemia, and an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for use in combination with an ammonia lowering agent, for use in the treatment or prevention of hyperammonemia.

In another aspect, the invention provides use of an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for the manufacture of a composition for the treatment or prevention of hyperammonemia, wherein the composition is for systemic administration.

In another aspect, the invention provides use of an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for the manufacture of a composition, for use in combination with an ammonia lowering agent, for the treatment or prevention of hyperammonemia.

In another aspect, the invention provides use of an ammonia lowering agent for the manufacture of a composition, for use in combination with an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for use in the treatment or prevention of hyperammonemia.

In another aspect, the invention provides a method of treating or preventing hyperammonemia in a subject, said method comprising systemic administration of an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof.

In another aspect, the invention provides a method of treating or preventing hyperammonemia in a subject, said method comprising administration of an

expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, and an ammonia lowering agent.

In another aspect, the invention provides a composition comprising an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for use in the treatment or prevention of hyperammonemia, wherein the composition is for systemic administration.

In a suitable embodiment, the composition may further comprise an ammonia lowering agent.

In another aspect, the invention provides a composition comprising an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for use in combination with an ammonia lowering agent, for use in the treatment or prevention of hyperammonemia.

In another aspect, the invention provides a composition comprising an ammonia lowering agent, for use in combination with an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, for use in the treatment or prevention of hyperammonemia.

In another aspect, the invention provides a kit comprising a with an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof, and a further therapeutic agent. Suitably, the further therapeutic agent may be an agent that is effective against hyperammonemia. Suitably the agent that is effective against hyperammonemia is an ammonia lowering agent or an amino acid or urea cycle intermediate thereof.

In another aspect, the invention provides a product comprising an expression vector encoding glutamine synthetase or a biologically active fragment or variant thereof and a further therapeutic agent, as a combined preparation for separate, simultaneous or sequential use in treating or preventing hyperammonemia. Suitably, the further therapeutic agent may be an agent that is effective against hyperammonemia. Suitably the agent that is effective against hyperammonemia is an ammonia lowering agent or an amino acid or urea cycle intermediate thereof. More suitably, the further therapeutic agent is a nitrogen scavenger.

In a suitable embodiment, the expression vector may be viral or non-viral. By way of example, a suitable viral expression vector may be derived from a virus selected from the group consisting of paramyxovirus, retrovirus, adenovirus, lentivirus, pox virus, alphavirus, and herpes virus. Other suitable viral vectors will be

known to those skilled in the art.

Suitable non-viral expression vectors may be selected from the group consisting of inorganic particle expression vectors (such as calcium phosphate, silica, and gold), lipid based particle expression vectors (for example cationic lipids, lipid nano emulsions, and solid lipid nanoparticles) and polymer based particle expression vectors (for example peptides, polyethylenimine, chitosan, and dendrimers). Other suitable non-viral expression vectors will be known to those skilled in the art.

Suitable systemic administration methods will be known to those skilled in the art. By way of example, systemic administration may be achieved by parenteral route of administration, such as intravenous or subcutaneous route. It will be appreciated that "systemic administration" allowed the product (such as glutamine synthetase or a biologically fragment thereof) of an expression vector to be expressed within multiple sites in the patient. In the context of the present invention, systemic administration does not include intramuscular administration.

The term "biologically active" refers to a fragment or variant of the nucleic acid encoding glutamine synthetase (SEQ ID NO: 1) exhibiting the ability to convert glutamate to glutamine. The protein according to SEQ ID NO: 1 is encoded by the nucleic acid sequence according to SEQ ID NO: 2. Thus, it will be appreciated that the vector, may comprise a fragment or variant of SEQ ID NO:2 which encodes a biologically active fragment or variant of glutamine synthetase.

The term "variant" as used herein refers to a polypeptide comprising an alteration of the primary structure of the polypeptide of SEQ ID NO: 1. Suitably, a variant may share 70% or more identity with the polypeptide of SEQ ID NO: 1; 80% or more identity with the polypeptide of SEQ ID NO: 1; 90% or more identity with the polypeptide of SEQ ID NO: 1; 95% or more identity with the polypeptide of SEQ ID NO: 1; 96% or more identity with the polypeptide of SEQ ID NO: 1; 97% or more identity with the polypeptide of SEQ ID NO: 1; 98% or more identity with the polypeptide of SEQ ID NO: 1; or even 99% or more identity with polypeptide of SEQ ID NO: 1. A variant may differ from the polypeptide of SEQ ID NO: 1 by 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 10% or more, 20% or more, or even 30% or more with reference to sequence according to SEQ ID NO: 1.

The term "fragment" as used herein refers to a polypeptide comprising an alteration to the length of the primary structure of the polypeptide of SEQ ID NO: 1. A suitable fragment may comprise at least 60%, at least 65%, at least 70%, at least

- 30 -

75%, at least 80%, at least 85%, at least 90%, or at least 95% of the full length of SEQ ID NO: 1. Indeed, a suitable variant may comprise at least 96%, at least 97%, at least 98%, or at least 99% of SEQ ID NO: 1.

5 It will be appreciated that (except where the context requires otherwise), embodiments described with reference to the GS protein for use in preventing hyperammonemia, the GS protein for use in combination with an ammonia lowering agent, ammonia lowering agent for use in combination with a GS protein, their uses, methods of treatment, compositions, kit and product, will generally be applicable, to the remaining aspects of the invention.

10 The present invention will now be further described with reference to the following non-limiting Examples and Figures in which:

Figure 1 shows the results of size exclusion chromatography (SEC) on a Superose 12 column of 20 kDa N-terminal aldehyde PEG conjugates of human GS protein as prepared in Example 1. The graph shows that multimers were eluted in
15 fractions 8 and 9, and monomer in fraction 10;

Figure 2 shows a comparison of the in-vitro GS activity of various GS candidates: PEG-conjugated variants (Trin GS1, Trin GS2, Trin GS3, Trin GS 4) versus non-conjugated GS (wt GS) and negative control. Glutamine Synthetase activity is shown as OD 570 nm according to the assay of Acosta *et al.*, 2009, World
20 J. Gastroenterol., 15(23), 2893-2899. Trin GS1 – (N-term Ald monomer); Trin GS2 – Nof-20; Trin GS3 – Nof-30, Trin GS4 – N-term Ald multimer;

Figure 3 shows PEG ELISA results on plasma pre- and post-dosing of male, wild-type (wt) CD1 mice of various conjugates at (A) baseline, (B) 24 hours post-dose and (C) 72 hours post-dose. (Trin1 – N-terminal Aldehyde conjugated GS
25 monomer; Trin2 – Nof-20 GS conjugated multimer; Trin 3 – Nof-30 conjugated GS multimer; Trin4 – N-terminal Aldehyde conjugated PEG multimer);

Figure 4 shows GS activity (OD 535nm) results in liver lysates in dosed wtCD1 mice at 2.5 mg/kg, 3 days post-dosing, as described in Example 3.

Figure 5 A shows liver GS activity assay results. Figure 5 B shows blood
30 plasma GS activity assay results. Both, liver and blood plasma GS activity was assayed in BDL rats treated with GS protein, and GS protein with nitrogen scavenger.

Figure 6 illustrates ammonia blood levels measured in BDL rats treated with GS protein, and GS protein with nitrogen scavenger.

Figure 7 illustrates a graph showing percentage of oedema in the prefrontal cortex in BDL rats treated with GS protein, or GS protein with nitrogen scavenger.

Figure 8 shows the results of a rotarod grip test in BDL rats treated with GS protein, or GS protein with nitrogen scavenger.

5 Figure 9 a graph showing ammonia levels in OTC mice treated with GS protein, or GS protein with nitrogen scavenger (SP- sodium phenylacetate).

Figure 10 shows the results of ammonia levels in plasma and liver GS activity in OTC mice treated with GS protein or DS protein with nitrogen scavenger (SP - sodium phenylacetate)

10

Example 1

Production and purification of GS protein and GS protein- PEG conjugates

15 Production of human glutamine synthetase (GS): pET30a+ vector, containing the gene for human GS (SEQ ID NO. 5 comprising a 5' sequence encoding a His-tag and the linker GGGGS at the N-terminal end of the GS and codon optimised for expression in bacteria) was used in an E. coli expression system. After plasmid construction, evaluation for the expression of GS was
20 performed with a wide range of induction (IPTG) and expression temperatures. Human GS was solubly expressed in the construct as detected by SDS-PAGE. Lysis buffer (50mM Tris pH 8.0, 10% glycerol, 0.1% Triton X-100, 100ug/ml lysozyme, 1mM PMSF, 3 Units DNase, 2mM MgCl) was used to extract soluble protein from cells. Soluble protein was extracted following centrifugation. After
25 expression studies, the best condition found with BL21 (DE3) cells, cultured and induced with 0.1 mM IPTG at 25 °C for 16 hours. Other conditions tried, included using varied IPTG induction (from 0.01M- 0.1M IPTG), various incubation temperatures (ranging from 16°C - 37°), and induction incubation times from 4-16 hours.

30 Purification of the expressed GS: the first step purification of the expressed protein comprised His tag purification with Ni-NTA beads, washing with 20 mM Imidazole, and elution with 300 mM Imidazole.

Protein PEG conjugation: the GS protein was conjugated under reducing conditions (with the use of 20 mM Sodium Cyano borohydride) to N-terminal
35 aldehyde 20kDa peg for 16 hours (Dr Reddy's 20kDa N-terminal Aldehyde PEG).

Final purification: Conjugated protein was further purified using SEC chromatography. A Superose 6 or Superose 12 column (see Figure 1) was used. Multimers were found in fractions 8+9. Fraction 10 in Superose 12 comprised (dilute) multimer. In Superose 6, multimers were found in fractions 8+9 and monomer in fractions 12/13.

A final formulation of the GS in PBS, pH 7.4 containing trehalose and sucrose was prepared.

Example 2

Activity of GS preparations

Various GS preparations and PEG conjugates prepared according to Example 1 were tested for GS activity using the assay of Acosta *et al.*, 2009 (supra), modified from the original assay described in Ehrenfeld et al., 1963, J. Biol. Chem. 238(11), 3711-3716.

100ug of purified protein sample was added to the following reaction buffer: 150 µL stock solution (100 mmol/L imidazole-HCl buffer [pH7.1], 40 mmol/L MgCl₂, 50 mmol/L, β-mercaptoethanol, 20 mmol/L ATP, 100 mmol/L, glutamate and 200 mmol/L hydroxylamine, adjusted to pH 7.2) Tubes were incubated at 37°C for 15 min. The reaction was stopped by adding 0.6 mL [2x concentration] ferric chloride reagent (0.37 mol/L FeCl₃, 0.67 mol/L HCl and 0.20 mol/L trichloroacetic acid). Samples were placed for 5 minutes on ice. Precipitated proteins were removed by centrifugation at 10,000 g, and the absorbance of the supernatants was read at 535-570 nm against a reagent blank. The results are shown in Figure 2. Trin1 – (N-term Aldehyde monomer PEG of 20 kD size, obtained from Dr Reddy's); Trin2 – Nof-20 conjugated GS, which was conjugated to the GS protein with a monofunctional linear 20 kD PEG, NHS active ester, obtained from NOF corporation); Trin 3 – Nof-30, conjugated to the GS protein with a monofunctional linear 30 kD PEG, NHS active ester, obtained from NOF corporation) Trin4 – N-term Ald, GS multimers). Trin 4 (N-term Ald multimer) showed the best activity, with a very similar activity profile compared to the wt GS (non-conjugated), though activity of other conjugates was similar.

Example 3

Dosing of GS protein to mice – effects on plasma levels of GS protein-PEG conjugates

5

Male, wild-type (wt) CD1 mice were dosed at 2.5 mg/kg with subcutaneous (s.c) dosing of various GS protein and PEG conjugates prepared as described in Example 1 (Trin1 – N-terminal Aldehyde conjugated GS monomer; Trin2 – Nof-20 GS conjugated multimer; Trin 3 – Nof-30 conjugated GS multimer; Trin4 – N-terminal Aldehyde conjugated PEG multimer). The ELISA was conducted according to the protocol outlined by the manufacturer (Abcam PEG ELISA kit, ab133065). Results of the plasma ELISA, as shown in Figure 3, show either very low or undetectable levels for unconjugated wt GS, as expected at all timepoints. After 24 hours, several candidates were found to be at a high level in plasma; however, after 72 hours post-dosing, Trin-GS 4 (N-terminal Aldehyde conjugated PEG GS multimer) showed the highest presence. N=2 animals in each group. Thus, this experiment shows that systemic administration of GS protein may be used successfully to obtain high circulating levels of the GS PEG conjugates, and in particular at levels which may be therapeutically effective or active.

20

Example 4

Dosing of GS protein to mice – GS activity levels of liver lysates

25

The activity assay was performed as described in Example 2, with the exception that 500 µg of liver lysate (from culled mice from the experiment of Example 3) was added to each reaction where appropriate. The results are shown in Figure 4. The GS activity results in liver lysates 3 days post-dosing demonstrate that the superior candidate was the N-terminal aldehyde conjugated PEG GS multimer, which was the only candidate to show significant activity above baseline compared to the vehicle (saline-dosed) control. N=2 animals in each group.

30

Example 5

- 34 -

5 The Otc^{spf-ash} Mouse model of urea cycle disorder (OTC deficiency) was used to show the effects of GS and GS+SP. The details of the mice used can be found at <https://www.jax.org/strain/001811> (B6EiC3Sn a/A-Otc^{spf-ash}/J). They are fed normal chow. The ages were variable from about 10 weeks to 23 weeks, with groups well-matched. All animals are male hemizygous (as OTC is X-linked, it is present only on the X chromosome of the males, therefore the mice are knockout).

10 All groups (vehicle, GS and GS+SP; where GS = Glutamine synthetase, GS + SP = Glutamine Synthetase + Sodium Phenylacetate) were treated as follows:
The experiment ran from a Tuesday until the following Wednesday (8 days).
SP was dosed i.p. 350mg/kg twice daily; GS was dosed in all treated groups for the first 4 days (i.p. @ 40mg/kg once daily), then a break of 2 days [a weekend], and 3 more days of dosing with GS @ 40mg/kg i.p.
15 Mice were culled on day 8, and blood extracted, spun down for plasma, and this plasma was used for ammonia quantitation (see method below).

Genotyping is performed using standard methods described in the literature.

20 Materials and Methods

All experiments were performed in accordance with the Animals (Scientific Procedures) Act of 1986, which was revised according to the European Directive 2010/63/EU. All animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication 86-23; revised 1985). All the animals used in these experiments were Male Sprague-Dawley rats (body weight, 250g at the beginning of the experiments) were obtained from Charles River Laboratories (Kent, UK) and divided into 5 groups: bile duct ligated animals + ammonia + saline serum
25 (BDL+HA+SS, n = 6), bile duct ligated animals + ammonia + sodium phenylacetate (BDL+HA+SP, n = 6), bile duct ligated animals + ammonia + sodium phenylacetate + glutamine synthetase (BDL+HA+SP+GS, n = 5), bile duct ligated animals + ammonia + glutamine synthetase (BDL+HA+ GS, n = 6), sham-operated animals + glutamine synthetase (SHAM+GS, n =5). Treatment comprising SP and GS may be
30 referred to as "COMBO".
35

Bile Duct Ligation Surgery

Under general anesthesia (5% isoflurane in 100% oxygen for induction, 2% isoflurane in air for maintenance) rats underwent triple ligation of the bile duct (way of a small laparotomy) to induce chronic liver injury and were studied 28 days after surgery. A midline abdominal incision was made under anesthesia. In the BDL group, the common bile duct was isolated, triply ligated with 3-0 silk, and sectioned between the ligatures. The sham-operated group performed the same procedure without the sectioning between the ligatures. After BDL all animals continued to gain weight and were comparable with sham controls. The overall mortality in both groups was less than 10% and occurred within 36 hours of the operation.

Noncirrhotic Hyperammonemia Condition

Twenty-three rats were administered a hyperammonemic (HA) diet. The amino acid recipe used for a stock of approximately 100 g was: 15 g leucine, 7.7 g phenylalanine, 7 g glutamate, 10 g alanine, 4.4 g proline, 5.8 g threonine, 11 g aspartate, 5 g serine, 4.8 g glycine, 3.3 g arginine, 9.6 g lysine, 8.4 g histidine, 3 g tyrosine, 1.5 g tryptophan, and 10.6 g valine. 25 g of this mix (mixed 1:5 with standard rodent chow powder) was freshly prepared daily and rats were given free access to it for 5 days. The recipe approximates the amino acid composition of a rodent haemoglobin, [1] mimicking the effect of gastrointestinal bleeding, which is known to result in systemic hyperammonemia [2].

Sodium Phenylacetate Condition

Eleven rats were administered a sodium phenylacetate (SP) diet. 0.3 g/kg a day for 5 days was mixed with the chow powder and freshly prepared daily.

Glutamine synthetase Condition

Sixteen rats were injected with GS intraperitoneally every two days (day 1 and day 3). The total volume injected was 3mls i.p., which allows for 18-22 mg/kg of GS.

Blood sampling and Biochemistry

Plasma samples were collected from the leg vein at different timepoints in all groups. The timepoints were counted after the treatment with glutamine synthetase as follows: 6 hours, 24 hours, 48 hours and 5 days. Analyses were conducted for plasma ammonia levels in every timepoint using 200 µl of respective plasma using a Cobas Integra 400 multi-analyser with the appropriate kits (Roche-diagnostics, Burgess Hill, West Sussex, UK).

10 Brain Edema

This was measured using the dry weight technique as described previously [3, 4]. Briefly, oven dried Eppendorf's were weighed with a sensitive electronic scale, then prefrontal cortex, striatum, hippocampus, cerebellum and cortices of each animal were placed into each respectively labelled Eppendorf and reweighed; all samples were within 0.1 mg difference. The dry weight was determined after Eppendorf's loaded with individual brain samples were dried in an oven at 60°C for 7 days. Tissue water content was then calculated as $\%H_2O = (1 - \text{dry wt/wet wt}) \times 100\%$.

20

Test for assessment locomotor activity: RotaRod-accelerod test

This test of motor performance consists of a motor-driven rotating rod that enables us to assess motor coordination and resistance to fatigue (Jones and Roberts 1968). The accelerating rotarod 7750 of Ugo Basile (Ugo Basile Biological Research Apparatus, Italy) was used for the rats. The procedure followed has two parts. In the first one, the animals were placed in the apparatus and the speed was maintained constant at 2 rpm for 60s. In the second part, the rats were evaluated for 5 min in the accelerod test session, in which the rotation rate constantly increased until it reached 20 rpm. Latency to fall off the rod and the actual rotation speed were recorded in the pre- and post-treatment conditions for all groups after 1 hour treatment.

35 Ammonia determination in blood using the TCA direct method

The method described in the paper (*Clin Chim Acta. 1968 Oct;22(2)183-86*) was used to measure plasma ammonia concentration, as follows.

Principle

5

In an alkaline solution ammonium ions react with hypochlorite to form monochloramine. In the presence of phenol and an excess of hypochlorite, the monochloramine will form a blue coloured compound, indophenol, when nitroprusside is used as a catalyst. The concentration of ammonium is determined spectrophotometrically at 630nm.

10

Method

15

Dissolve 3.5g of phenol and 0.04g sodium nitroprusside in 100ml distilled water to prepare reagent A.

Dissolve 1.8g sodium hydroxide in 48mls in distilled water and add 4mls of 1M sodium hypochlorite solution to prepare reagent B.

Add 150µl of 5% TCA to 50µl to each plasma sample and centrifuge at 10,000RPM at 4°C for 10 minutes. Take 50µl of the supernatant and put in 96 well plate to which is added 50µl of both reagents A and B.

20

Standard ammonium chloride concentrations for the calibration curve are made by dissolving ammonium chloride in distilled water and serially diluting to make concentrations ranging from 400µmol to 3µmol. Distilled water is used as the blank. The well plate is covered from light and incubated at 50°C for 60 minutes.

25

Absorbance is measured at 630nm using a spectrophotometer to determine the ammonia concentration.

Results

30

Dosing of GS protein to mice – GS activity levels in liver and blood

The activity assay was performed as described in the materials and methods section above. The results are shown in Figure 5A and B. The results in rat liver measured at day 5, show that GS activity is best in the SHAM+GS group.

35

Additionally, it can be seen from Figure 5A that GS and GS+SP treatment

- 38 -

increase GS activity in the livers of mice which have undergone BDL. When measured in blood, the results show that GS activity is best in the BDL+GS group. Additionally, from Figure 5B, it can be seen that GS activity in blood is consistent over time, even 24hrs and 48hrs post dosing.

5

Dosing of GS protein to mice – ammonia concentrations in the BDL rat

As seen in Figure 6, ammonia levels are highest in the BDL rat. Treatment with GS, GS+SP, and SP, each resulted in a significant reduction of ammonia levels in the blood. GS reduced ammonia levels following 2 doses. Treatment with GS+SP reduced the ammonia levels most significantly, suggesting a synergistic effect.

10

Dosing of GS protein to mice – brain swelling in the BDL rat

15

Brain oedema was measured in the prefrontal cortex. Treatment with GS was found to reduce brain oedema most significantly compared to treatment with SP, and even treatment with SP+GC (Figure 7). Treatment with SP did not statistically significantly reduce the swelling as compared to the control (i.e. BDL mice without treatment).

20

Dosing of GS protein to mice – brain and physical function in the BDL rat

Figure 8 shows the results of a rotarod grip test. Surprisingly, GS dosing was found to improve performance in all tested mice groups. Treatment with SP alone did not lead to statistically significant effects, but treatment with GS + SP shows the best improvement, suggesting a synergistic effect.

25

Treatment of mice with OTC deficiency

30

As shown in Figure 9, ammonia is very significantly decreased in the treated groups.

In Figure 10, it is seen that in the OTC mice treated with GS or GS & SP, plasma GS activity increased from 0.2 in the vehicle group, to 0.8 in GS only group and

35

- 39 -

~1.1 in the GS & SP group. Liver GS activity increased from ~0.175 in the vehicle group, to ~2.8 in GS only group and ~2.5 in the GS & SP group

Summary of results

- 5 In summary, the administered GS is biocompatible, safe and improves blood and liver GS activity. It also leads to a reduction in ammonia and brain oedema, as well as improves neurocognitive and/or physical function. Additionally, the data suggests that treatment with SP and GS may have a synergistic effect.

10 References

- [1] Riggs A. The amino acid composition of some mammalian hemoglobins: mouse, guinea pig, and elephant. J Biol Chem 1963;238:2983-2987.
- 15 [2] Balata S, Olde Damink SW, Ferguson K, Marshall I, Hayes PC, Deutz NE, Williams R, Wardlaw J, Jalan R. Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis. Hepatology 2003;37:931-939.
- 20 [3] Stewart-Wallace AM. A biochemical study of cerebral tissue, and of changes in cerebral oedema. Brain 1939; 62: 426–38.
- [4] Traber PG, Ganger DR, Blei AT. Brain edema in rabbits with galactosamine-induced fulminant hepatitis. Regional differences and effects on intracranial
- 25 pressure. Gastroenterology 1986; 91: 1347–56.

SEQUENCES:

SEQ ID NO. 1 [Full human protein]

30 MTTSSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEP
 KCVEELPEWNFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVF
 KYNRRPAETNLRHTCKRIMDMVSNQHPWFGMEQEYTLMGTDGHPFGWPS
 NGFPGPQGPYYCGVGADRAYGRDIVEAHYRACLYAGVKIAGTNAEVMMPAQ
 35 WEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIATFDPKPIPGNWNAGAGCH
 TNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDPKGGGLDNARRLTGFHE

- 40 -

TSNINDFSAGVANRSASIRIPRTVGQEKKG YFEDRRPSANCDPFSVTEALIRT
 CLLNETGDEPFQYKN

5 **SEQ ID. NO. 2 (ONLY Methionine is cleaved for the mature protein in vivo):**

TTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTL DSEPK
 CVEELPEWNFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVFK
 YNRRPAETNLRHTCKRIMDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSN
 10 GFPGPQGPYYCGVGADRAYGRDIVEAHYRACLYAGVKIAGTNAEVM PAQ
 WEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIA TFDPKPIPGNWNGAGCH
 TNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDPKGGLDNARRLTGFHE
 TSNINDFSAGVANRSASIRIPRTVGQEKKG YFEDRRPSANCDPFSVTEALIRT
 15 CLLNETGDEPFQYKN

15 **SEQ ID NO. 3 cDNA**

CGAGAGTGGGAGAAGAGCGGAGCGTGTGAGCAGTACTGCGGCCTCCTCTCCTCTCCTAAC
 CTGCTCTCGCGGCCTACCTTTACCGCCCGCCTGCTCGGCGACCAGAACACCTTCCACCA
 20 TGACCACCTCAGCAAGTTCCCACCTAAATAAAGGCATCAAGCAGGTGTACATGTCCCTGC
 CTCAGGGTGAGAAAGTCCAGGCCATGTATATCTGGATCGATGGTACTGGAGAAGGACTGC
 GCTGCAAGACCCGACCCTGGACAGTGAGCCCAAGTGTGTGGAAGAGTTGCCTGAGTGGA
 ATTTTCGATGGCTCCAGTACTTTACAGTCTGAGGGTTCCAACAGTGACATGTATCTCGTGC
 CTGCTGCCATGTTTCGGGACCCCTTCCGTAAGGACCCTAACAAAGCTGGTGTATGTGAAG
 25 TTTTCAAGTACAATCGAAGGCCTGCAGAGACCAATTTGAGGCACACCTGTAAACGGATAA
 TGGACATGGTGAGCAACCAGCACCCCTGGTTTGGCATGGAGCAGGAGTATACCTCATGG
 GGACAGATGGGCACCCCTTTGGTTGGCCTTCCAACGGCTTCCAGGGCCCGAGGTCCAT
 ATTACTGTGGTGTGGAGCAGACAGAGCCCTATGGCAGGGACATCGTGGAGGCCCATTAAC
 GGGCCTGCTTGTATGCTGGAGTCAAGATTGCGGGGACTAATGCCGAGGTCATGCCTGCCC
 30 AGTGGGAATTTTCAAGATTGGACCTTGTGAAGGAATCAGCATGGGAGATCATCTCTGGGTGG
 CCCGTTTCATCTTGCATCGTGTGTGTGAAGACTTTGGAGTGATAGCAACCTTTGATCCTA
 AGCCCATTCCTGGGAAC TGGAATGGTGCAGGCTGCCATACCAACTTCAGCACCAAGGCCA
 TGCGGGAGGAGAATGGTCTGAAGTACATCGAGGAGGCCATTGAGAACTAAGCAAGCGGC
 ACCAGTACCACATCCGTGCCTATGATCCCAAGGGAGGCC TGGACAATGCCGACGTCTAA
 35 CTGGATTCCATGAAACCTCCAACATCAACGACTTTTCTGGTGGTGTAGCCAATCGTAGCG
 CCAGCATACGCATTCGCCGAC TGTGGCCAGGAGAAGAAGGGTTACTTTGAAGATCGTC
 GCCCCCTCTGCCAACTGCGACCCCTTTTCGGTGACAGAAGCCCTCATCCGCACGTGTCTTC
 TCAATGAAACCGCGATGAGCCCTTCCAGTACAAAAATTAAGTGGACTAGACCTCCAGCT
 40 GTTGAGCCCTCCTAGTTCTTCATCCCACTCCAACCTCTTCCCCCTCTCCAGTTGTCCCG
 ATTTGTAAC TCAAAGGGTGGAATATCAAGGTCGTTTTTTTTTCATTCC

SEQ ID NO. 4: GS protein grown in bacteria, used in Example 1

45 MGSSHHHHHHHGGGSM TTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDG
 TGEGLRCKTRTL DSEPKCVEELPEWNFDGSSTLQSEGSNSDMYLVPAAMFR
 DPFKDPNKLVLCEVFKYNRRPAETNLRHTCKRIMDMVSNQHPWFGMEQE
 YTLMGTDGHPFGWPSN GFPGPQGPYYCGVGADRAYGRDIVEAHYRACLYA
 GVKIAGTNAEVM PAQWEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIA T
 50 FDPKPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYD
 PKGGLDNARRLTGFHETSNINDFSAGVANRSASIRIPRTVGQEKKG YFEDRR
 PSANCDPFSVTEALIRTCLLNETG DEPFQYKN

SEQ ID NO. 5 cDNA (bacterial optimised cDNA used in Example 1).

5
ATGGGCAGCAGCCACCACCATCACCACCACGGCGGCGGCGGTAGCATGA
CCACCTCGGCAAGCAGCCACCTGAATAAAGGCATCAAACAGGTGTATAT
GTCTCTGCCGCAGGGTGAAAAAGTTCAAGCCATGTACATTTGGATCGAT
GGCACCGGTGAAGGCCTGCGTTGCAAAACCCGCACGCTGGACTCAGAAC
10 CGAAATGTGTGGAAGAAGTCCGGAATGGAACCTTGATGGTAGCTCTAC
GCTGCAGTCGGAAGGCAGTAATTCGACATGTATCTGGTTCCGGCGGCC
ATGTTTCGTGATCCGTTCCGCAAAGACCCGAACAACTGGTGCTGTGCG
AAGTTTTTAAATACAACCGTCGCCCCGGCGGAAACCAATCTGCGTCATAC
GTGTAAACGCATTATGGATATGGTCAGCAACCAGCACCCGTGGTTCGGT
15 ATGGAACAAGAATATACCCTGATGGGTACGGATGGCCATCCGTTTGGTT
GGCCGAGCAATGGTTTCCCGGGTCCGCAGGGTCCGTATTACTGCGGTGTC
GGCGCAGATCGTGCTTACGGTCGCGACATTGTGGAAGCACACTATCGTG
CTTGTCTGTACGCGGGTGTTAAAATCGCCGGCACCAATGCAGAAGTCAT
GCCGGCTCAGTGGGAATTTCAAATTGGCCCGTGCGAAGGTATCAGCATG
20 GGCGATCATCTGTGGGTGCTCGTTTCATCCTGCACCGCGTCTGTGAAGA
TTTTGGTGTGATTGCGACCTTCGACCCGAAACCGATCCCGGGCAACTGGA
ATGGTGCTGGCTGCCATACCAACTTTAGCACGAAAGCGATGCGTGAAGA
AAATGGCCTGAAATACATCGAAGAAGCAATCGAAAAACTGTCTAAACGT
CATCAGTATCACATTCGCGCCTACGATCCGAAAGGCGGTCTGGACAACG
25 CACGTCGCCTGACCGGTTTTACGAAACGAGCAACATCAATGATTTCTCT
GCGGGCGTTGCCAATCGCTCAGCCTCGATTTCGTATCCCGCGCACCGTCGG
TCAAGAGAAAAAAGGCTATTTTGAAGATCGTCGCCCGAGTGCAAACGTGT
GACCCGTTCTCCGTGACGGAAGCCCTGATCCGCACCTGTCTGCTGAATGA
AACCGGCGATGAACCGTTCCAATACAAAAAT
30

SEQ ID NO. 6 [*Lactobacillus acidophilus* strain 30SC GS]

35 >tr|F0TG87|F0TG87_LACA3 Glutamine synthetase OS=Lactobacillus acidophilus
(strain 30SC)
MSKQYTTEEIRKEVADKDVRFLRLCFTDINGTEKAVEVPTSQLDKVLNNDIR
FDGSSIDGFVRLEESDMVLYPDFSTWSVLPWGDEHGGKIGRLICSVHMTDG
KPFAGDPRNNLKRVLGEMKEAGFDTFDIGFEMEFHLFKLDENGNNWTEVPD
40 HASYFDMTSDDEGARCRREIVETLEEIGFEVEAAHHEVGDGQQEIDFRFDDA
LTTADRCQTFKMVARHIARKHGLFATFMAKPVEGQAGNGMHNNMSLFKN
KHNVFYDKDGEFHLNNTALYFLNGILEHARAITAIGNPTVNSYKRLIPGEAP
VYIAWAAKNRSPLVRIPSAGEINTRLEMRSADPTANPYLLLAACLTAGLKGI
KEQKMPMKPVEENIFEMTEEERAHEGKPLPTTLHNAIKAFKEDDLIKSALG
45 EHLTHSFIESKELEWSKYSQSVSDWERQRYMNW

SEQ ID NO. 7 [*Zea Mays* GS] (corn/Maize GS)

- 42 -

>tr|B4G1P1|B4G1P1_MAIZE Glutamine synthetase

MACLTDLVNLNLSDNTEKIIAEYIWIGGSGMDLRSKARTLSGPVTDPSKLPK
WNYDGSSTGQAPGEDSEVILYPQAIFKDPFRRGNNILVMCDCYTPAGEPIPT
5 NKRYNAAKIFSSPEVAAEEPWYGIEQEYTLQKDTNWPLGWPIGGFPGPQG
PYYCGIGAEEKSFGRDIVDAHYKACLYAGINISGINGEVMPGQWEFQVGPSV
GISSGDQVWVARYILERITEIAGVVVTFDPKPIPGDWNGAGAHTNYSTESMR
KEGGYEVIKAAIEKLKLRHREHIAAYGEGNERRLTGRHETADINTFSWGVA
10 NRGASVRVGRETEQNGKGYFEDRRPASNMDPYVVTSMIAETTHWKP

15

20

25

30

35

40

Claims:

1. A pharmaceutical composition comprising a glutamine synthetase fusion
5 protein, comprising i) glutamine synthetase and ii) a peptide comprising a) the
sequence HHHHHH (6xHis) and b) a linker comprising 2-10 amino acids and
comprising the sequence GGGGS; wherein the peptide is provided at the N
terminal end of the glutamine synthetase protein and wherein the glutamine
10 synthetase protein is or comprises the protein of SEQ ID NO. 1 or a variant thereof
having glutamine synthetase enzyme activity and at least 90% sequence identity to
the sequence of SEQ ID NO. 1; and a pharmaceutically acceptable excipient.
2. A pharmaceutical composition according to claim 1, wherein the glutamine
synthetase protein of claim 1 i) comprises 373 or 372 amino acids.
15
3. A pharmaceutical composition according to claim 2 wherein the glutamine
synthetase protein lacks the N terminal methionine.
4. A pharmaceutical composition according to any one of claims 1 to 3 wherein
20 the fusion protein is linked to a moiety.
5. A pharmaceutical composition according to claim 4, wherein the moiety is
selected from a protein, a peptide, a non-protein polymer or an affinity tag.
- 25 6. A pharmaceutical composition according to claim 5, wherein the moiety is
PEG.
7. A pharmaceutical composition according to claim 6, wherein PEG is
conjugated to the peptide.
30
8. A pharmaceutical composition according to claim 6 or 7 wherein PEG is a
20kDa N-terminal aldehyde PEG.

9. A pharmaceutical composition according to any one of claims 1 to 8 wherein the peptide of claim 1 ii) is, or comprises, the sequence MGSSHHHHHHGGGGS or GSSHHHHHHGGGGS.
- 5 10. A pharmaceutical composition comprising a glutamine synthetase fusion protein which
- i) comprises the sequence of SEQ ID NO. 4; or
- ii) comprises the sequence of SEQ ID NO. 4 with a deletion of the N-terminal methionine and having glutamine synthetase activity; or
- 10 iii) is encoded by the sequence of SEQ ID NO. 5;
- iv) is encoded by the sequence of SEQ ID NO. 5 and has a deletion of the N-terminal methionine and has glutamine synthetase activity;
- and a pharmaceutical excipient.
- 15 11. A pharmaceutical composition according to any one of the preceding claims, wherein the glutamine synthetase fusion protein is in a form suitable for systemic non-oral administration.
- 20 12. A pharmaceutical composition according to any one of claims 1 to 11, wherein the glutamine synthetase fusion protein is in a form suitable for parenteral or subcutaneous administration.
- 25 13. A pharmaceutical composition according to any one of claims 1 to 12, wherein the glutamine synthetase fusion protein is in a multimeric form or monomeric form.
14. A pharmaceutical composition according to any one of claims 1 to 13 for use in therapy.
- 30 15. A glutamine synthetase (GS) fusion protein as defined in any one of claims 1 to 10.
16. A glutamine synthetase fusion protein according to claim 15, wherein the fusion protein is in a multimeric form or a monomeric form.

17. Use of a glutamine synthetase (GS) fusion protein as defined in any one of claims 1 to 16 in the manufacture of a medicament for treating or preventing hyperammonemia by systemic non-oral administration to a subject.
- 5 18. The use according to claim 17, wherein said medicament is to be administered in combination with a compound which removes ammonia or reduces or inhibits production of ammonia.
- 10 19. The use according to claims 17 or 18, wherein the GS protein is not to be administered to muscle.
- 15 20. The use according to any one of claims 17 to 19, wherein the hyperammonemia arises due to a urea cycle disorder (UCD) and/or glutamine synthetase deficiency, or is associated with organ failure or arises due to non-alcoholic fatty liver disease, hepatic encephalopathy, acute liver failure, liver cirrhosis, and/or kidney dysfunction and/or failure.
- 20 21. Use of a GS fusion protein as defined in any one of claims 1 to 16 for the manufacture of a composition for use in combination therapy for the treatment or prevention of hyperammonemia, wherein said medicament is to be administered in combination with a compound which removes ammonia or reduces or inhibits production of ammonia.
- 25 22. Use of a GS fusion protein as defined in any one of claims 1 to 16 in the manufacture of a first medicament and use of a compound which removes ammonia or reduces or inhibits production of ammonia in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy for the treatment or prevention of hyperammonemia.
- 30 23. The use according to claims 21 or 22, wherein the hyperammonemia arises due to a urea cycle disorder (UCD) and/or glutamine synthetase deficiency, or is associated with organ failure or arises due to non-alcoholic fatty liver disease, acute liver failure, liver cirrhosis, and/or kidney dysfunction and/or failure.

24. The use according to any one of claims 21 to 23, wherein the GS protein is a glutamine synthetase fusion protein as defined in any one of claims 1 to 22.

5 25. The use according to any one of claims 21 to 24, wherein the compound which removes ammonia or reduces or inhibits production of ammonia is selected from the group consisting of a compound which reduces the amount of nitrogen, an ion exchange resin (for example Relapsa), an ammonia absorber (such a liposomal based ammonia absorber, for example Versantis), an engineered microbiome that removes ammonia (for example Synlogic), Rifaximin and Lactulose.

10

26. The use according to any one of claims 21 to 25, wherein the compound which reduces the amount of nitrogen is selected from the group consisting of: a pharmaceutically acceptable salt of phenylacetic acid or a pharmaceutically acceptable pro-drug thereof, a pharmaceutically acceptable salt of phenylbutyric acid pharmaceutically acceptable pro-drug thereof, glycerol phenylbutyrate pharmaceutically acceptable pro-drug thereof, a pharmaceutically acceptable salt of benzoic acid or a pharmaceutically acceptable pro-drug thereof, and ammonia binding resin, most suitably wherein the pharmaceutically acceptable salt of phenylacetic acid is sodium phenylacetate.

20

27. A kit comprising i) a glutamine synthetase fusion protein as defined in any one of claims 1 to 16 for systemic non-oral administration and ii) a compound which removes ammonia or reduces or inhibits production of ammonia or an amino acid or urea cycle intermediate or analogue thereof, preferably wherein the compound which removes ammonia or reduces or inhibits production of ammonia is selected from the group consisting of a compound which reduces the amount of nitrogen, an ion exchange resin (for example Relapsa), an ammonia absorber (such a liposomal based ammonia absorber, for example Versantis), an engineered microbiome that removes ammonia (for example Kaleido Biosciences KB195), Rifaximin and Lactulose.

30

28. An expression vector encoding a glutamine synthetase fusion protein according to any one of claims 1 to 16.

29. Use of an expression vector according to claim 28 in the manufacture of a medicament for the treatment or prevention of hyperammonemia, wherein the vector is for systemic administration.
- 5 30. A kit comprising an expression vector according to claim 29, and a further therapeutic agent, preferably wherein the therapeutic agent is a compound which removes ammonia or reduces or inhibits production of ammonia or an amino acid or urea cycle intermediate thereof.
- 10 31. A microbial cell comprising an expression vector according to claim 29.